Kiadis Pharma N.V. Overview
Pro stress-test →Kiadis Pharma NV is a biopharmaceutical company focused on development of therapies for patients with life-threatening diseases. The company develops off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. Kiadis focuses on addressing significant unmet medical needs in hematologic malignancies and inherited blood disorders.
Strategic Profile
Pro stress-test →The company's PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions, while its off-the-shelf NK-cell platform is based on NK cells from unique universal donors. Kiadis develops K-NK003 for the treatment of relapse/refractory acute myeloid leukemia, and K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT.
Competitive Landscape
Pro stress-test →The NK cell therapy space remains nascent with limited direct competitors currently in late-stage development. Primary indirect competition comes from CAR-T cell therapy leaders including Novartis (Kymriah), Gilead/Kite (Yescarta), and emerging NK platform companies. The broader immuno-oncology landscape includes traditional checkpoint inhibitor manufacturers and other cell therapy modalities.
Industry Context
Kiadis Pharma N.V. operates in NK cell immunotherapy.
Key facts
Founded: 1997 · Headquarters: Amsterdam, Netherlands · Employees: N/A · Revenue: N/A · Market cap: N/A